Mr. John Hennessy:

To the best of my memory, that is what happened in the case of Orkambi, but Mr. Judge may have a little more information on that.

I might ask Professor Barry to deal with the question about genetic services and the issues concerning biosimilars the Deputy has raised. There is a lot of information available on both, but on biosimilars in particular.

To respond to the question the Deputy raised about weighting and drug tenders, outside of the normal reimbursement process I am not aware of too many drugs in respect of which we embark on a tendering process with a competitive supplier. I am aware of one or two but I will have to check further the weighting of the price within that. The Deputy has indicated it is 25% here as opposed to 80% elsewhere.